[1] |
SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng.
Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
|
[2] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[3] |
WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi.
560 cases of adverse drug reaction/event caused by Mailu Shutong pills
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
|
[4] |
ZHAO Jun, DONG li, WANG Yang, LIANG Yu, YANG Xue, LI Enze.
Adverse reaction/event reports of esmolol
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 925-930.
|
[5] |
ZHANG Qian, YUN Yuan, HE Lian.
Pharmaceutical care of hyperprolactinemia in a patient induced by risperidone
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 936-938.
|
[6] |
CHAO Ying, ZHANG Xuemei, ZHANG Chengjian, WANG Bei.
One case of ureterolith combined with gallstone caused by Ceftriaxone sodium for injection in children
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 943-945.
|
[7] |
GUO Haiyan, HE Bo, YAN Hongli, YANG Xueting.
One case of persistent hiccup caused by Wenxin Keli
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 946-948.
|
[8] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|
[9] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[10] |
LIU Yadi, ZHANG Xiaomeng, CAI Haili, CHEN Siying, WANG Yu, ZHANG Bing.
Traditional Chinese medicine for prevention and treatment of adriamycin cardiotoxicity and an empirical study of evidence elements
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 759-764.
|
[11] |
CAI Haili, ZHANG Xiaomeng, LIU Yadi, LIU Shujia, GAO Fujun, WANG Yu, ZHANG Bing.
Progress in construction and evaluation of a drug-induced cardiotoxicity model
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 765-770.
|
[12] |
CHENG Yijing, LI Tao, LIU Junting, HUANG Guimin, ZHONG Xuli, LIN Aihua, PAN Shoudong, LI Long, BAI Dongsheng, ZHAN Xiaojun, LIU Zhenjiang, REN Wei, TAI Jun.
Safety evaluation of haemocoagulase agkistrodon for injection in children based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 787-790.
|
[13] |
ZHAO Jie, GAO Ming'e, CHANG Hong, FAN Huixia.
Two cases of allergic reactions in children caused by compound polyethylene glycol electrolyte powder
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 816-818.
|
[14] |
ZHANG Xian, QU Jianchang, ZHAO Qiang, XU Xin, MA Rui.
One case of hyponatremia induced by venlafaxine hydrochloride sustained-release capsules
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 819-821.
|
[15] |
NIE Xiaolu, MA Jingyao, SUN Feng, ZHAN Siyan.
Pathogenesis and diagnosis of drug-induced thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 829-835.
|